CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Review CIRB
Study Status
Study Number Sort descending Lead Group Study Title CIRB Study Status
GOG-0250 GOG A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Bevacizumab (NSC #704865; IND #113912) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus. NCI Supplied Agent: Bevacizumab (NSC #704865; IND #113912) NCT#01012297 Adult CIRB - Late Phase Emphasis Completed
GOG-0252 GOG A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian; Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC #704865; IND #113912) Adult CIRB - Late Phase Emphasis Completed
GOG-0258 GOG A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked; Advanced Endometrial Carcinoma Adult CIRB - Late Phase Emphasis Available to Open
GOG-0261 GOG A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV; Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus; Fallopian Tube; Peritoneum or Ovary Adult CIRB - Late Phase Emphasis Completed
GOG-0262 GOG GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel In Combination With Carboplatin With Or Without Concurrent and Consolidation Bevacizumab (NSC #704865; IND #113912) in the Treatment of Primary Stage II; III OR IV Epithelial Ovarian; Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging To Evaluate Treatment Response in Patients Participating in GOG-0262 Adult CIRB - Late Phase Emphasis Available to Open
GOG-0263 GOG Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk; Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy Adult CIRB - Late Phase Emphasis Available to Open
GOG-0275 GOG A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia Adult CIRB - Late Phase Emphasis Completed
GOG-0277 GOG A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NCS# 123127) versus Observation for Uterus-Limited; High Grade Uterine Leiomyosarcoma Adult CIRB - Late Phase Emphasis Completed
GOG-0281 GOG A Randomized Phase II/III Study To Assess The Efficacy of Trametinib (GSK 1120212) In Patients With Recurrent Or Progressive Low-Grade Serous Ovarian Cancer Or Peritoneal Cancer. NCT # NCT02101788 Adult CIRB - Late Phase Emphasis Available to Open
GOG-0286B GOG A Randomized Phase II/III Study Of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo As Initial Therapy For Measurable Stage III Or IVA; Stage IVB; or Recurrent Endometrial Cancer Adult CIRB - Late Phase Emphasis Available to Open